ArticleWorld journal of gastrointestinal surgery2025
Compound spleen-tonifying composition alleviates dextran sulfate sodium-induced ulcerative colitis in rats.
Article in World journal of gastrointestinal surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUlcerative colitis (UC) is a chronic relapsing inflammatory bowel disease with rising global incidence. Current therapies for UC often provide incomplete relief and are associated with adverse side effects, highlighting the need for alternatives with increased safety and effectiveness. Compound spleen-tonifying composition (CSTC) contains ingredients, such as
aimTo study the therapeutic effect and mechanism of CSTC in dextran sulfate sodium (DSS)-induced UC in rats.
methodsSprague-Dawley rats were freely given 4% DSS solution for seven days to establish the UC model. After intervention with CSTC and its different solvent extracts, body weight changes, the disease activity index (DAI), and colon histopathology were assessed to evaluate therapeutic outcomes. The contents of superoxide dismutase (SOD), malondialdehyde (MDA), myeloperoxidase (MPO), glutathione peroxidase (GSH-px), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) in colon tissue were determined to investigate changes in biochemical indicators.
resultsDSS administration triggered severe UC symptoms, including weight loss, colon shortening, elevated DAI scores, and histological damage. These symptoms were accompanied with oxidative stress (reduced SOD and GSH-px levels and increased MDA and MPO levels), inflammation (elevated TNF-α, IL-1β, and IL-6 levels), and a reduction in the expression levels of tight junction proteins [zonula occludens-1 (ZO-1) and occluding]. High- and medium-dose CSTC treatment significantly alleviated clinical symptoms, restored colon morphology, normalized oxidative stress markers, suppressed proinflammatory cytokines, and enhanced ZO-1 and occludin levels, demonstrating dose-dependent efficacy. Notably, solvent extraction critically influenced bioactivity: Nonpolar extracts (chloroform and petroleum ether) showed minimal effects, whereas polar extracts (ethyl acetate and
conclusionThe above findings highlight CSTC's multifaceted anti-UC effects, which are mediated through oxidative stress mitigation and cytokine modulation, while emphasizing the polarity-dependent efficacy of its extracts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.